Results 261 to 270 of about 12,063,985 (329)

Enhancing Post-Exercise Oxygen Kinetics Modeling With Physiological Bounds and Manual V̇O₂__baseline Input: A Novel Approach. [PDF]

Eur J Sport Sci
Ulupınar S, İnce İ, Gençoğlu C, Özbay S, Çabuk S.   +4 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Exploring the applicability of "One-Size-Fits-All" road transport decarbonization strategies: a participatory energy systems modeling comparison of urban and non-urban municipalities. [PDF]

Sci Rep
de Oliveira Laurin M, Aryanpur V, Farabi-Asl H, Grahn M, Taljegard M, Vilén K.   +5 more
europepmc   +1 more source

MIF as an oncogenic driver of low‐heterogeneity melanomas

Molecular Oncology, EarlyView.
Shvefel and colleagues identified tumor‐secreted macrophage migration inhibitory factor (MIF) as an upregulated cytokine that mediates immune resistance in melanomas with low‐intratumoral heterogeneity. MIF and its functional paralogue D‐dopachrome tautomerase (D‐DT or MIF‐2) have overlapping but nonidentical signaling functions and are hypothesized to
Thuy T. Tran, Gabriela Athziri Sánchez‐Zuno, Rajan P. Kulkarni, Harriet M. Kluger, Richard Bucala   +4 more
wiley   +1 more source

AlphaPulldown2-a general pipeline for high-throughput structural modeling. [PDF]

Bioinformatics
Molodenskiy D, Maurer VJ, Yu D, Chojnowski G, Bienert S, Tauriello G, Gilep K, Schwede T, Kosinski J.   +8 more
europepmc   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

A simulation-based framework for modeling and prediction of personalized blood pressure trajectories in hypertensive patients after antihypertensive treatment. [PDF]

PLoS One
Hunsdieck B, Mielke J, Ickstadt K, Elçi E.   +3 more
europepmc   +1 more source

XXI.—Notice of Two Models and Sections of about Eleven Square Miles, forming a part of the Mineral Basin of South Wales, in the Vicinity of Pontypool, and presented to the Geological Society [PDF]

Richard Cowling Taylor
openalex   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

A Model Is a Model

Strategy Science, 2019
Knudsen, Thorbjorn, Levinthal, Daniel A., Puranam, Phanish   +2 more
openaire   +2 more sources